Fortrea (NASDAQ:FTRE) Price Target Cut to $12.00 by Analysts at Barclays
Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...
StockStory.org on MSN3d
Why Fortrea (FTRE) Shares Are Plunging Today
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company ...
Fortrea price target lowered to $12 from $25 at Barclays
Barclays lowered the firm’s price target on Fortrea (FTRE) to $12 from $25 and keeps an Equal Weight rating on the shares.Discover the Best ...
Fortrea (NASDAQ:FTRE) Price Target Lowered to $11.00 at The Goldman Sachs Group
Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...
Multibillion-dollar public company shakes up board amid stock slump
A Durham company with a slumping stock is implementing changes to its board after reaching a deal with an activist investor.
Fortrea Shares at Record Low on Outlook for 2025 Revenue Decline
Shares of Fortrea Holdings sank to a new low after the company said it expects revenue to drop this year. The stock fell 31% to a new all-time low of $9.55 in the first half of the trading day. The ...
Fierce Biotech10d
Fortrea's Alaric Jackson Talks AI in Clinical Trials
In a recent interview with Fierce Biotech's Chris Hayden, Fortrea's Chief Technology and Data Officer Alaric Jackson ...
Morningstar2d
Fortrea Faces Spin-Related Challenges in the Near Term; Positive Long-Term Outlook
Fortrea is a global, late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions.
Fortrea price target lowered to $12 from $25 at Baird
Baird lowered the firm’s price target on Fortrea (FTRE) to $12 from $25 and keeps a Neutral rating on the shares. The firm updated its model ...